Mechanisms of long COVID and the path toward therapeutics.
| Autor: | Peluso MJ; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: michael.peluso@ucsf.edu., Deeks SG; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: steven.deeks@ucsf.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cell [Cell] 2024 Oct 03; Vol. 187 (20), pp. 5500-5529. Date of Electronic Publication: 2024 Sep 25. |
| DOI: | 10.1016/j.cell.2024.07.054 |
| Abstrakt: | Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symptoms following infection with SARS-CoV-2, is a newly recognized infection-associated chronic condition that causes disability in some people. Substantial progress has been made in defining its epidemiology, biology, and pathophysiology. However, there is no cure for the tens of millions of people believed to be experiencing long COVID, and industry engagement in developing therapeutics has been limited. Here, we review the current state of knowledge regarding the biology and pathophysiology of long COVID, focusing on how the proposed mechanisms explain the physiology of the syndrome and how they provide a rationale for the implementation of a broad experimental medicine and clinical trials agenda. Progress toward preventing and curing long COVID and other infection-associated chronic conditions will require deep and sustained investment by funders and industry. Competing Interests: Declaration of interests M.J.P. has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics and Shionogi outside the submitted work. S.G.D. reports consulting for Enanta Pharmaceuticals, BioVie, and Pfizer and reports research support from Aerium Therapeutics outside the submitted work. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|